Latest Autoantibody Stories

Innovative and high quality product lines set new benchmarks for the autoimmune disease diagnostics market LONDON, April 30, 2013 /PRNewswire/ -- Based on its recent analysis of the autoimmune disease diagnostics market, Frost & Sullivan recognises Euro Diagnostica AB with the 2013 Europe Product Differentiation Excellence Award. "Euro Diagnostica offers a range of high-quality enzyme linked immunosorbent assay (ELISA) kits for autoimmune diagnostics," noted Frost &...

BREDA, The Netherlands and GHENT, Belgium, April 24, 2013 /PRNewswire/ -- First program based on proprietary ABDEG(TM) technology to promote degradation and clearance of disease-causing autoantibodies arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed its second product candidate this year into formal preclinical development. Complementing its...

HAYWARD, Calif., March 27, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced it has initiated the CHABLIS-SC1 Phase 3 study of blisibimod, a novel inhibitor of B-Cell Activating Factor (BAFF) for the treatment of systemic lupus erythematosus (lupus). Lupus is a chronic autoimmune disease, which often leads to severe skin rash,...

Partners to Develop Novel Nuclease Proteins for Lupus OSAKA, Japan and SEATTLE, Feb. 27, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and Resolve Therapeutics, LLC ("Resolve") today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases. The lead compound, RSLV-132, a novel nuclease(*1) Fc fusion protein(*2), will begin...

NEW YORK, Jan. 31, 2013 /PRNewswire/ -- The Lupus Research Institute (LRI) - world's leading supporter of innovative research in lupus -- today awards $3.6 million in Novel Research Grants to allow 12 investigators to pursue ground-breaking studies with potential for transformative results. The $300,000 grants provide scientists with the resources to devote their talent to lupus research for three years. In just its first decade of service, the LRI has awarded more than $40 million...

LEIDEN, The Netherlands and SAN DIEGO, Jan. 29, 2013 /PRNewswire/ -- Leiden University Medical Center (LUMC) and INOVA Diagnostics are pleased to announce the completion of an exclusive, worldwide license agreement for technology developed at LUMC to detect antibodies to carbamylated proteins (anti-CarP). This technology represents an important advance in the diagnosis of Rheumatoid Arthritis (RA). "The detection of autoantibodies in sera of RA patients has provided important...

SAN DIEGO, Jan. 22, 2013 /PRNewswire/ -- INOVA Diagnostics is pleased to announce the full commercial launch of BIO-FLASH, a rapid-response chemiluminescent analyzer for use by clinical reference and hospital laboratories. This signals the global release of BIO-FLASH along with QUANTA Flash® reagents for autoimmune disease diagnostic testing. BIO-FLASH is a technologically advanced analyzer which offers full automation of a broad menu of highly accurate QUANTA Flash immunoassays...

GLEN ALLEN, Va., Jan. 7, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) announced today the preliminary results of the Company's ASAP (Anatabloc Supplementation Autoimmune Prevention) Human Thyroid Study that analyzes the impact of anatabine dietary supplementation on thyroid health. (Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO ) The study is a three-month, five-visit, double-blind, placebo-controlled study of the impact of anatabine dietary...

SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Genalyte, Inc. today announced that it has been awarded a Small Business Innovation Research (SBIR) grant to develop multiplexed diagnostic assays for the early detection and monitoring of Type 1 diabetes that will run on Genalyte's innovative Maverick(TM)Detection System. The $500,000 grant is from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health. Genalyte's novel...

NATICK, Mass., Nov. 12, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., leading the new field of nuclear transport modulators, announces an oral presentation on the use of its SINE CRM1 antagonists for the treatment of systemic lupus erythematosus. Jennifer Anolik, MD, PhD, Associate Professor of Medicine, Department of Medicine at the University of Rochester (New York), is presenting "Novel nuclear export inhibitors deplete autoreactive plasma cells and protect mice with lupus...